FDA human factors guidance for devices
Decision brief
Answer first · skim in under a minute
FDA released guidance that provides a risk-based framework for the human factors information to include in medical device marketing submissions. The document also recommends the content of human factors engineering and usability engineering information for FDA review.
FDA’s human factors guidance for medical device marketing submissions is now final. The May 2026 document gives manufacturers a risk-based framework for what human factors (HF) information to include in 510(k), De Novo, PMA, and HDE filings—and sets an August 1, 2026 transition for expecting the newly recommended content.
Contents9 sections
Key Takeaways
- Final guidance title: Content of Human Factors Information in Medical Device Marketing Submissions.
- Federal Register availability notice: May 29, 2026 (Docket FDA-2015-D-4599).
- Applies to 510(k)s, De Novo requests, PMAs, and HDEs reviewed by CDRH.
- Transition: submissions received before August 1, 2026 generally need not include all new recommended items yet.
What problem does the guidance solve?
Sponsors have long faced uncertainty about when HF validation data belong in a marketing file—especially for 510(k)s. The final guidance gives a clear risk-based map. Sponsors and FDA reviewers can then agree on how much HF documentation a change needs.
FDA published the guidance page here: Content of Human Factors Information in Medical Device Marketing Submissions.
When does the August 1, 2026 date matter?
The Federal Register notice (May 29, 2026) states FDA recognizes industry may need about 60 days to operationalize the policies. For filings already pending after publication and those received before August 1, 2026, FDA generally does not anticipate manufacturers will be ready to include all newly recommended information—while still reviewing any HF packages voluntarily submitted.
How should sponsors use the companion 2016 guidance?
FDA positions the new submission-content guidance as a companion to Applying Human Factors and Usability Engineering to Medical Devices. That earlier document explains how to run HF/usability engineering; the 2026 final focuses on what to document in the marketing submission itself.
Draft guidance first appeared December 9, 2022 (87 FR 75635). FDA says it revised the final text based on comments, including additional risk-based factors for HF Submission Category assignment, new examples and appendices, and scope clarifications.
What changes for RA and HF teams?
Teams should map each product to an HF Submission Category using the decision flowchart, confirm whether critical-task/use-related hazard changes trigger deeper validation packages, and align eSTAR template fields that now capture HF category selection. Combination products with device constituent parts fall in scope when CDRH reviews the marketing submission.
What remains unproven
Guidance is not binding regulation. Category assignment still requires sponsor judgment; FDA may request more data after filing. Whether Decision Point D reduces validation submissions without increasing QMSR inspection scrutiny will only be clear after post-August 2026 review cycles.
Related NovaPharma coverage
- FDA EUA for nitenpyram New World screwworm treatment
- FDA guidance on sharing potential NDA patent information
- FDA draft guidance on payor communications
Frequently Asked Questions
What is the FDA human factors marketing guidance?
FDA’s final guidance “Content of Human Factors Information in Medical Device Marketing Submissions” provides a risk-based framework for the human factors information manufacturers should include in CDRH marketing submissions such as 510(k)s, De Novo requests, PMAs, and HDEs.
When does FDA expect the new HF information?
The Federal Register notice published May 29, 2026. For submissions pending after publication and those received before August 1, 2026, FDA generally does not expect manufacturers to already include all newly recommended information, though it will review such information if submitted.
How does this relate to the 2016 HF engineering guidance?
FDA says the new document is intended as a companion to the final guidance “Applying Human Factors and Usability Engineering to Medical Devices,” which covers how to apply HF/usability engineering methods, while the 2026 guidance focuses on what HF information to put in marketing submissions.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
